A cost effective decision analysis model comparing two strategies for maintaining hepalitis B immunity in hemodialysis patients

2001 ◽  
Vol 120 (5) ◽  
pp. A556-A556
Author(s):  
S WESTON ◽  
S SAAB ◽  
D LY ◽  
M BREZINA ◽  
H YEE ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Cost Effective ◽  
Hemodialysis Patients ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Effective Decision

A cost effective decision analysis model comparing two strategies for maintaining hepalitis B immunity in hemodialysis patients

2001 ◽  
Vol 120 (5) ◽  
pp. A556
Author(s):  
Shiobhan R. Weston ◽  
Sammy Saab ◽  
David Ly ◽  
Maria Brezina ◽  
Hal F. Yee ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Cost Effective ◽  
Hemodialysis Patients ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Effective Decision

Percutaneous Stenting of Incidental Unilateral Renal Artery Stenosis: Decision Analysis of Costs and Benefits

2003 ◽  
Vol 10 (3) ◽  
pp. 546-556 ◽  
Author(s):  
David A. Axelrod ◽  
A. Mark Fendrick ◽  
Ruth C. Carlos ◽  
Robert J. Lederman ◽  
James B. Froehlich ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Decision Analysis ◽  
Renal Artery ◽  
Incremental Cost ◽  
Renal Artery Stenosis ◽  
Cost Effective ◽  
Artery Stenosis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Refractory Hypertension

Purpose: To determine the incremental cost-effectiveness of prophylactic percutaneous transluminal angioplasty with stent placement (PTA-S) in patients with incidentally discovered, asymptomatic renal artery stenosis (RAS) compared to delaying PTA-S until patients develop refractory hypertension or renal insufficiency (therapeutic PTA-S). Methods: The Markov decision analysis model was used to determine the incremental cost per quality adjusted life year (QALY) saved for prophylactic PTA-S as compared to therapeutic PTA-S in a hypothetical cohort of patients with 50% unilateral atherosclerotic RAS followed from age 61 to death. Results: Prophylactic PTA-S compared to therapeutic PTA-S results in more QALYs/patient (10.9 versus 10.3) at higher lifetime costs ($23,664 versus $16,558). The incremental cost effectiveness of prophylactic PTA-S was estimated to be $12,466/QALY. Prophylactic stenting was not cost effective (>$50,000/QALY) if the modeled incidence of stent restenosis exceeded 15%/year and the incidence of progression in the contralateral renal artery was <2% of arteries/year. Conclusions: PTA-S of incidental, asymptomatic unilateral RAS may improve patients' quality of life at an acceptable incremental cost. However, this technology should be used hesitantly until a randomized comparison confirms its effectiveness.

Cost Benefit and Utility Decision Analysis of Turbinoplasty with Adenotonsillectomy for Pediatric Sleep-Disordered Breathing

2019 ◽  
Vol 161 (2) ◽  
pp. 343-347 ◽  
Author(s):  
Grace Baik ◽  
Scott E. Brietzke
Keyword(s):  
Sensitivity Analysis ◽  
Decision Analysis ◽  
Sleep Disordered Breathing ◽  
Treatment Success ◽  
Cost Benefit ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Baseline Model ◽  
Turbinate Hypertrophy ◽  
Disordered Breathing

Objectives Use decision analysis techniques to assess the potential utility gains/losses and costs of adding bilateral inferior turbinoplasty to tonsillectomy/adenoidectomy (T/A) for the treatment of obstructive sleep-disordered breathing (oSDB) in children. Use sensitivity analysis to explore the key variables in the scenario. Study Design Cost-utility decision analysis model. Setting Hypothetical cohort. Subjects and Methods Computer software (TreeAge Software, Williamstown, Massachusetts) was used to construct a decision analysis model. The model included the possibility of postoperative complications and persistent oSDB after surgery. Baseline clinical and quality-adjusted life year (QALY) parameters were estimated using published data. Cost data were estimated from Centers for Medicare and Medicaid 2018 databases ( www.cms.gov ). Sensitivity analyses were completed to assess for key model parameters. Results The utility analysis of the baseline model favored the addition of turbinoplasty (0.8890 vs 0.8875 overall utility) assuming turbinate hypertrophy was present. Sensitivity analysis indicated the treatment success increase (%) provided by concurrent turbinoplasty was the key parameter in the model. A treatment success increase of 3% of turbinoplasty was the threshold where concurrent turbinoplasty was favored over T/A alone. The incremental cost-effectiveness ratio (ICER) of $27,333/QALY for the baseline model was favorable to the willingness-to-pay threshold of $50,000 to $100,000/QALY for industrialized nations. Conclusions The addition of turbinoplasty for children with turbinate hypertrophy to T/A for the treatment of pediatric oSDB is beneficial from both a utility and cost-benefit analysis standpoint even if the benefits of turbinoplasty are relatively modest.

Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database

1995 ◽  
Vol 109 (1) ◽  
pp. 177-188 ◽  
Author(s):  
Paul C. Adams ◽  
James C. Gregor ◽  
Ann E. Kertesz ◽  
Leslie S. Valberg
Keyword(s):  
Decision Analysis ◽  
Blood Donors ◽  
Hereditary Hemochromatosis ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Model Based

scholarly journals Cost-Effectiveness of Universal Prophylaxis in Pregnancy with Prior Group B Streptococci Colonization

2009 ◽  
Vol 2009 ◽  
pp. 1-11 ◽  
Author(s):  
Mark A. Turrentine ◽  
Mildred M. Ramirez ◽  
Joan M. Mastrobattista
Keyword(s):  
Early Onset ◽  
Positive Culture ◽  
Cost Effective ◽  
Decision Analysis Model ◽  
Analysis Model ◽  
Group B Streptococci ◽  
Neonatal Deaths ◽  
History Of ◽  
Group B ◽  
Universal Treatment

Objective. To estimate the costs and outcomes of rescreening for group B streptococci (GBS) compared to universal treatment of term women with history of GBS colonization in a previous pregnancy.Study Design. A decision analysis model was used to compare costs and outcomes. Total cost included the costs of screening, intrapartum antibiotic prophylaxis (IAP), treatment for maternal anaphylaxis and death, evaluation of well infants whose mothers received IAP, and total costs for treatment of term neonatal early onset GBS sepsis.Results. When compared to screening and treating, universal treatment results in more women treated per GBS case prevented (155 versus 67) and prevents more cases of early onset GBS (1732 versus 1700) and neonatal deaths (52 versus 51) at a lower cost per case prevented ($8 805 versus $12 710).Conclusion. Universal treatment of term pregnancies with a history of previous GBS colonization is more cost-effective than the strategy of screening and treating based on positive culture results.

Sign in / Sign up

Export Citation Format

Share Document